| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SALEKI-GERHARDT AZITA | EVP, Operations | May 24 | Option Exercise | 34.93 | 86,920 | 3,036,230 | 203,204 | May 26 05:20 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | May 24 | Sale | 116.29 | 86,920 | 10,108,033 | 116,284 | May 26 05:20 PM | | Strom Carrie C | SVP & Pres Global Allerg Aesth | May 03 | Option Exercise | 41.39 | 4,184 | 173,176 | 63,409 | May 05 04:23 PM | | Strom Carrie C | SVP & Pres Global Allerg Aesth | May 03 | Sale | 112.40 | 4,184 | 470,282 | 59,225 | May 05 04:23 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Mar 02 | Option Exercise | 54.86 | 170,113 | 9,332,399 | 546,710 | Mar 02 08:27 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Mar 01 | Sale | 108.59 | 19,514 | 2,119,041 | 0 | Mar 02 08:31 PM | | Sorg Elaine K. | SVP, US Commercial Operations | Mar 01 | Sale | 108.61 | 8,440 | 916,642 | 17,595 | Mar 02 08:30 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Mar 01 | Sale | 108.61 | 170,113 | 18,476,204 | 376,597 | Mar 02 08:27 PM | | Stewart Jeffrey Ryan | SVP, US Commercial Operations | Mar 01 | Sale | 108.59 | 13,773 | 1,495,576 | 50,969 | Mar 02 08:26 PM | | Sorg Elaine K. | SVP, US Commercial Operations | Feb 22 | Option Exercise | 89.78 | 20,195 | 1,813,052 | 52,946 | Feb 24 06:28 PM | | Sorg Elaine K. | SVP, US Commercial Operations | Feb 22 | Sale | 104.72 | 20,195 | 2,114,732 | 32,751 | Feb 24 06:28 PM | | Stewart Jeffrey Ryan | EVP, Commercial Operations | Dec 29 | Option Exercise | 51.42 | 25,290 | 1,300,412 | 76,259 | Dec 31 01:15 PM | | Stewart Jeffrey Ryan | EVP, Commercial Operations | Dec 29 | Sale | 105.00 | 25,290 | 2,655,450 | 50,969 | Dec 31 01:15 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Nov 27 | Option Exercise | 51.42 | 51,990 | 2,673,326 | 51,990 | Dec 01 05:22 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Nov 27 | Sale | 105.00 | 51,990 | 5,458,950 | 0 | Dec 01 05:22 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Nov 20 | Sale | 99.38 | 40,000 | 3,975,046 | 20,006 | Nov 24 05:34 PM | | ALBAN CARLOS | Vice Chairman | Nov 16 | Option Exercise | 35.88 | 115,830 | 4,155,980 | 230,729 | Nov 18 05:04 PM | | ALBAN CARLOS | Vice Chairman | Nov 16 | Sale | 100.00 | 115,830 | 11,583,000 | 114,899 | Nov 18 05:04 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Nov 12 | Option Exercise | 57.12 | 194,154 | 11,089,858 | 512,796 | Nov 12 05:54 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Nov 12 | Sale | 97.10 | 194,154 | 18,851,790 | 318,642 | Nov 12 05:54 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | Nov 10 | Sale | 98.00 | 17,426 | 1,707,748 | 96,441 | Nov 12 05:56 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Nov 09 | Sale | 95.74 | 37,450 | 3,585,463 | 318,642 | Nov 12 05:54 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | Nov 04 | Sale | 93.61 | 4,800 | 449,328 | 109,067 | Nov 06 04:29 PM | | SEVERINO MICHAEL | Vice Chairman | Nov 04 | Sale | 93.61 | 90,679 | 8,488,461 | 67,281 | Nov 06 04:29 PM | | ALBAN CARLOS | Vice Chairman | Jul 07 | Sale | 100.00 | 53,325 | 5,332,555 | 114,899 | Jul 08 09:19 PM |
|
